Home Featured Page 118

Featured

Latest

Weekly Psychedelic Policy Briefing: October 12, 2026

The Psychedelic Practitioner Issue 7: Preparedness (Systems)

Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names

Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic Public Health

Psychedelic Bulletin #136: MindMed Collaborators Share Topline LSD for MDD Results;...

Psychedelics Weekly – Breaking Convention, Decolonizing the Psychedelic Space, and How...

atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late...

The Psychedelic Mind: How Neuroscience Can Help You Navigate Your Inner...

Clearmind Medicine Forms a Data and Safety Monitoring Board to Oversee...

PT407 – The Planet, Psychedelics, and Psyche: Optimism in Ecology

Reunion Neuroscience Announces Presentation at 2023 Bloom Burton & Co. Healthcare...

FILAMENT HEALTH ANNOUNCES SPRING 2023 EVENT AND MEDIA APPEARANCES

BetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting...

Algernon Pharmaceuticals Reminds Shareholders of Previously Announced Rights Offering and Approaching...

EDITOR PICKS

Weekly Psychedelic Policy Briefing: October 12, 2026

The Psychedelic Practitioner Issue 7: Preparedness (Systems)

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Weekly Psychedelic Policy Briefing: October 12, 2026

How to Change Your Behavior

The Psychedelic Practitioner Issue 7: Preparedness (Systems)

Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names

Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic Public Health

Psychedelic Bulletin #136: MindMed Collaborators Share Topline LSD for MDD Results;...

Psychedelics Weekly – Breaking Convention, Decolonizing the Psychedelic Space, and How...

atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late...

The Psychedelic Mind: How Neuroscience Can Help You Navigate Your Inner...

Clearmind Medicine Forms a Data and Safety Monitoring Board to Oversee...

PT407 – The Planet, Psychedelics, and Psyche: Optimism in Ecology

Reunion Neuroscience Announces Presentation at 2023 Bloom Burton & Co. Healthcare...

FILAMENT HEALTH ANNOUNCES SPRING 2023 EVENT AND MEDIA APPEARANCES

BetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting...

Algernon Pharmaceuticals Reminds Shareholders of Previously Announced Rights Offering and Approaching...

EDITOR PICKS

Weekly Psychedelic Policy Briefing: October 12, 2026

How to Change Your Behavior

The Psychedelic Practitioner Issue 7: Preparedness (Systems)

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY